Tumor necrosis (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines that promotes apoptosis. TRAIL induces apoptosis via death receptors (DR4 and DR5) in a wide variety of tumor cells but not in normal cells. The objectives of this study are to investigate the intracellular mechanisms by which TRAIL induces apoptosis. The death receptor Fas, upon ligand binding, trimerizes and recruits the adaptor protein FADD through the cytoplasmic death domain of Fas. FADD then binds and activates procaspase-8. It is unclear whether FADD is required for TRAIL-induced apoptosis. Here we show that the signaling complex of DR4/DR5 is assembled in response to TRAIL binding. FADD and caspase-8, but not caspase-10, are recruited to the receptor, and cells de®cient in either FADD or caspase-8 blocked TRAIL-induced apoptosis. In addition, TRAIL initiates the activation of caspases, the loss of mitochondrial transmembrane potential (Dc m ), the cleavage of BID, and the redistribution of mitochondrial cytochrome c. Treatment of Jurkat cells with cyclosporin A delayed TRAIL-induced Dc m , caspase-3 activation and apoptosis. Similarly, Overexpression of Bcl-2 or Bcl-X L delayed, but did not inhibit, TRAIL-induced Dc m and apoptosis. In contrast, XIAP, cowpox virus CrmA and baculovirus p35 inhibited TRAIL-induced apoptosis. These data suggest that death receptors (DR4 and DR5) and Fas receptors induced apoptosis through identical signaling pathway, and TRAIL-induced apoptosis via both mitochondrial-dependent and -independent pathways. Oncogene (2001) 20, 2122 ± 2133.
Introduction
The tumor necrosis factor (TNF) superfamily consists of proteins involved in proliferation, dierentiation, and apoptosis (Krammer, 1999) . The members of this superfamily, TNF-a, CD95L (FasL/APO-1L), and TRAIL/APO-2L have been shown to directly induce apoptosis (Wiley et al., 1995; Pitti et al., 1996; Peter and Krammer, 1998; Krammer, 1999) . Unlike TNF and FasL, TRAIL appears to have a unique selectivity for triggering apoptosis in tumor cells while leaving normal tissues intact. Like CD95L and TNF-a, TRAIL induces apoptosis in various tumor cell lines in vitro (Tanaka et al., 1997; Walczak et al., 1997; Bodmer et al., 2000; Kim et al., 2000) , but is less eective at inducing apoptosis in non-transformed cells (Gura, 1997; French and Tschopp, 1999; Walczak et al., 1999; Kim et al., 2000) . In mice, administration of TRAIL was eective at reducing mammary adenocarcinoma growth without any of the toxic eects shown with administration of FasL or TNF (Walczak et al., 1999) . Thus, TRAIL might be an eective agent for cancer treatment. However, relatively little is known about the signaling events activated by TRAIL, including the adaptor molecule(s) and initial caspase(s).
TRAIL binds to several distinct receptors: (a) TRAIL-R1 (DR4/APO-2 A) (Pan et al., 1997b) ; (b) TRAIL-R2 (DR5/TRICK/Killer) (Pan et al., 1997b; Schneider et al., 1997a; Screaton et al., 1997; Sheridan et al., 1997; Walczak et al., 1997; Wu et al., 1997) ; (c) TRAIL-R3 (DcR1/TRID/LIT) (Degli-Esposti et al., 1997b; Schneider et al., 1997a) ; (d) TRAIL-R4 (DcR2/ TRUNDD) (Degli-Esposti et al., 1997a) ; and (e) osteoprotegerin (Emery et al., 1998) . Both DR4 and DR5 contain the intracellular death domain (DD) essential for the induction of apoptosis following receptor ligation (Golstein, 1997; Pan et al., 1997b; Schneider et al., 1997a; Walczak et al., 1997; Wu et al., 1997) . In contrast, neither DcR1 nor DcR2 mediate apoptosis due to a complete or partial lack of the intracellular DD, respectively (Degli-Esposti et al., 1997a,b; Marsters et al., 1997; Pan et al., 1997a; Sheridan et al., 1997) . Osteoprotegerin is a soluble receptor for TRAIL and thus blocks TRAIL-induced apoptosis (Emery et al., 1998) .
Death receptor cytoplasmic sequences contain a shared 80-amino acid death domain that, upon ligand binding, associates with a similar domain found in adaptor proteins such as FAS-associating protein with death domain (FADD) and TNF-related associated death domain (TRADD) (Golstein, 1997; Grith and Lynch, 1998; Schulze-Ostho et al., 1998) . The adaptor proteins also contain an eector domain that constitu-tively binds to cysteine proteases (caspases) that cleave speci®c proteins. The two caspases predominantly bound to these adaptor molecules are caspase 8 and caspase 10 (Ashkenazi and Dixit, 1998; Schulze-Ostho et al., 1998) . Once recruited by association of adaptor proteins with death receptors the caspases are transproteolyzed, resulting in their activation. Caspase-8 or caspase 10 activation initiates a cascade where other caspases, including caspase-3, are activated, ultimately resulting in an irreversible commitment of cells to undergo apoptosis (Ashkenazi and Dixit, 1998; Schulze-Ostho et al., 1998) .
Binding of TRAIL to DR4 and DR5 leads to the recruitment of an adaptor protein bound to a caspase. The role of FADD in TRAIL receptors is highly controversial. Complexes of FADD and caspase 8 have been implicated in DR4-and DR5-induced apoptosis (Schneider et al., 1997a; Wajant et al., 1998) ; however, there is also evidence suggesting they might not be required for DR4-and DR5-induced apoptosis. In FADD7/7 mice, cells are still capable of undergoing apoptosis upon ligation of DR4 and DR5, implicating the involvement of another FADD-like adaptor protein (Yeh et al., 1998) . However, since transfection of death-receptors often leads to non-speci®c aggregation of their death domains, it is still not clear if FADD is involved in the physiological setting of TRAIL-induced apoptosis. In contrast, FAS signaling is well de®ned and involves recruitment of the FADD-caspase 8 complex to the activated receptor (Schulze-Ostho et al., 1998) .
To explore the mechanism of TRAIL-induced apoptosis, we investigated the range of intracellular events that took place in response to TRAIL receptor engagement in Jurkat and U937 leukemia cells and MCF-7 breast carcinoma cells. TRAIL signals apoptosis through FADD and caspase-8. Exposure of Jurkat cells to recombinant TRAIL triggered apoptosis accompanied by activation of multiple caspases, cleavage of several caspase substrates, loss of mitochondrial membrane potential, cleavage of BID, and release of cytochrome c from mitochondria. Antiapoptotic genes Bcl-2 and Bcl-X L delayed, but did not block, TRAIL-induced apoptosis. XIAP inhibited TRAIL-induced caspase-3 activity. Cowpox virus CrmA, and baculovirus p35 also inhibit TRAILinduced apoptosis. Thus, TRAIL can induce apoptosis in mitochondrial-dependent and -independent manners.
Results

Formation of DISC by TRAIL
Because the death-inducing signaling complex (DISC) is recruited to activated Fas , we ®rst tested the possibility of DISC formation in cells expressing endogenous proteins in response to TRAIL treatment (Figure 1 ). Jurkat cells were treated with sTRAIL for various time-periods, the TRAILreceptor DISC was immunoprecipitated and assayed for proteins known to be involved in Fas signaling. Jurkat T cells express DR5, but not DR4, cDNA (Schneider et al., 1997b) . We found that only DR5 bound to immunoprecipitated TRAIL in Jurkat cells ( Figure  1a) . Recruitment of FADD and caspase-8 to activated DR5 was detected as early as 5 min. DR5 and caspase-10 were not found in the TRAIL-DISC of Jurkat cells The assembled death inducing signaling complex (DISCs) were immunoprecipitated with anti-5X His antibody and protein A sepharose, and analysed by Western blotting using antibodies to DR4, DR5, FADD, caspases-8 and -10. In unstimulated controls (7), sTRAIL was added after lysis to immunoprecipitate nonstimulated TRAIL receptors. Two distinct DR5 species, which probably correspond to the two alternatively spliced forms, were detected (Screaton et al., 1997) . Cell extracts were analysed for the presence of DR4 and DR5 receptors, FADD, caspases-8, and -10 before (7) and after (+) TRAIL addition for 30 min. (b) TRAIL-induced caspase-3 activity in a time-dependent manner. Jurkat cells were treated with sTRAIL (50 nM) for various time points and caspase-3 activity was measured as per the manufacturer's directions. The data represent mean+s.d. of three independent experiments. (c) TRAIL-induced apoptosis in a timeand dose-dependent manner. Jurkat cells were treated with sTRAIL for either 12 or 24 h, and apoptosis was measured by nucleosome ELISA assay as per the manufacturer's directions. The data represent mean+s.d. of three independent experiments Oncogene TRAIL-induced apoptosis A Suliman et al ( Figure 1a) . In contrast to caspase-8, processing of caspase-10 was not observed in the cytoplasm up to 60 min after TRAIL addition. TRAIL also induced caspase-3 activity in a time-dependent manner that followed caspase-8 activation (Figure 1a,b) . We next measured TRAIL-induced apoptosis by nucleosome ELISA assay (Srivastava et al., 1999c) . TRAIL-induced apoptosis in dose-and time-dependent manners ( Figure  1c ). These data suggest that FADD is a constituent of TRAIL-DISC, and caspase-8 and caspase-3 are activated in response to TRAIL treatment.
To con®rm the recruitment of FADD and caspase-8 to the TRAIL-DR5 DISC, we used mutant Jurkat T cells that lack either FADD or caspase-8 and are resistant to Fas-induced cell signals (Juo et al., 1998 (Juo et al., , 1999 . Incorporation of caspase-8 into TRAIL receptor DISC was defective in cells lacking caspase-8 or FADD (Figure 2a ). In addition, FADD can not be substituted by a FADD-like protein, and caspase 10 could not replace caspase-8 for DISC formation (data not shown). TRAIL-induced caspase-3 activity in wild type Jurkat cells, whereas it has no eect on caspase-3 activation in FADD-de®cient Jurkat cells (Figure 2b ).
Since TRAIL failed to activate caspase-3 in FADD de®cient Jurkat cells, we examined TRAIL-induced apoptosis in wild type, caspase-8 de®cient and FADD de®cient Jurkat cells. Wild type Jurkat cells were sensitive to TRAIL-induced apoptosis, whereas FADD-de®cient and caspase-8 de®cient Jurkat cells were resistant to TRAIL-induced apoptosis ( Figure  2c ). This resistance was due to a de®ciency in caspase-8 or in FADD expression rather than to reduced expression of caspase-3 or DR5 (Figure 2d ). TRAIL induced caspase-3 activity in wild type Jurkat cells, whereas it has no aect in caspase-8 de®cient or FADD de®cient cells (Figure 2d ). Thus, FADD recruitment to DISC and caspase-8 activation are necessary events during TRAIL-DR5 mediated apoptosis in Jurkat cells.
To exclude the possibility that the incorporation of FADD and caspase-8 is restricted to cells of lymphatic origin only, we studied DISC assembly in breast carcinoma MCF-7 cells. In contrast to Jurkat cells, TRAIL-receptor DISC from MCF-7 cells contains both DR4 and DR5 (Figure 3a ). In addition, FADD and caspase-8, but not caspase-10, were constituents of TRAIL-DISC (Figure 3a) . Caspase-8 and FADD were present in the cell extract of MCF-7 cells (Figure 3b ). TRAIL induced apoptosis in a dose-dependent manner in MCF-7 cells (Figure 3a ). Similar to Jurkat cells, wild type MCF-7 cells were sensitive to sTRAIL-induced apoptosis, whereas FADD-de®cient and caspase-8 de®cient MCF-7 cells were resistant to sTRAILinduced apoptosis (Figure 3c ). These data suggest that FADD is an important constituent of DISC in mediating TRAIL-induced apoptosis.
Caspase inhibitors inhibit TRAIL-induced apoptosis
To further investigate which caspases are responsible for TRAIL-induced apoptosis, we used speci®c caspase inhibitors. Caspase-8 inhibitor (z-IETD-fmk) and a pan inhibitor (z-VAD-fmk) completely inhibited TRAIL-induced apoptosis in Jurkat cells (Figure 4a ). By comparison, caspase-3 inhibitor (z-DEVD-fmk) partially inhibited TRAIL-induced apoptosis, and inactive peptide z-FA-fmk had no eect on apoptosis. Apparently, the more down downstream acting caspase-3 inhibitor z-DEVD-fmk is not as ecient in blocking TRAIL-induced cell death as inhibitors that directly target caspase-8.
We next examined whether caspase-8 is essential for activation of caspase-3 and measured the caspase-3 activity in the presence of caspase-8 speci®c inhibitor (z-IETD) (Figure 4b ). Whereas inactive peptide z-FAfmk had no eect on TRAIL-induced caspase-3 activity, caspase-8 inhibitor z-IETD-fmk completely blocked TRAIL-induced caspase-3 activity, suggesting that caspase-8 acts upstream of caspase-3 in TRAILinduced apoptosis.
Following TNFa or Fas treatment, BID, a BH3-domain-only molecule is cleaved at its amino terminus Luo et al., 1998; Gross et al., 1999; Han et al., 1999) . Cleavage of cytosolic p22 BID by caspase-8 generates a p15 fragment that translocates to the mitochondria. Truncated p15 BID (tBID) inserts into the membrane and immunodepletion of tBID from subcellular fractions argues that tBID is required for cytochrome c release from the mitochondria. We therefore examined the eects of TRAIL on BID cleavage in Jurkat cells. Treatment of Jurkat cells with TRAIL resulted in BID cleavage in a dose-dependent manner (Figure 4c ), suggesting that BID is a substrate for caspase-8. Since DNA repair enzyme poly(ADPribose) polymerase (PARP) is cleaved by caspases during apoptosis (Lazebnik et al., 1994; Martin and Green, 1995; Srivastava et al., 1999d) Mitochondrial permeability transition (MPT) refers to the regulated opening of a large, nonspeci®c pore in the inner mitochondrial membrane (Green and Reed, 1998) . The MPT causes the loss of the mitochondrial membrane potential (Dc m ) (Green and Reed, 1998) . The¯uorescent dye DiOC 6 (3) localizes to mitochondria and the MPT reduces the accumulation of DiOC 6 (3) as a consequence of the loss in Dc m (Green and Reed, 1998; Srivastava et al., 1999c) . In order to assess the involvement of mitochondria in TRAIL-induced apoptosis, we measured Dc m in the presence of various caspase inhibitors ( Figure 4d ). In contrast to z-LEHD-fmk (a caspase-9-speci®c inhibitor) and z-DEVD-fmk (a caspase-3 speci®c inhibitor), the caspase-8-speci®c inhibitor z-IETD-fmk was able to block TRAIL-induced loss of Dc m (Figure 4d ). These data show that caspase-8 links the apoptotic signal from the activated TRAIL-DR5 both to mitochondria (leading to dissipation of Dc m ) and directly to the downstream apoptosis-executing caspases.
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Cyclosporin A inhibits TRAIL-induced drop in mitochondrial membrane potential, caspase-3 activation and apoptosis
The opening of mitochondrial permeability transition pore (PTP) and the apoptotic process can be inhibited by a diverse group of agents such as bongkrekic acid, and cyclosporin A (CsA) (Susin et al., 1998) . Various doses of CsA (0.5 ± 10 mM) have been used to inhibit the mitochondrial PTP (Ichas and Mazat, 1998; Bernardi, 1999) . To determine the involvement of mitochondria in TRAIL-induced apoptosis, Jurkat cells were pretreated with CsA (10 mM) for 45 min before the addition of TRAIL (50 nM) for various time points, and mitochondrial membrane potential was measured ( Figure 5a ). CsA had no eect on TRAILinduced drop in Dc m upto 4 h, but signi®cantly inhibited Dc m after 4 h of TRAIL treatment ( Figure  5a ). Since mitochondrial proteins (such as cytochrome c and Apaf-1) play a major role in caspase activation, we sought to examine the eects of CsA on caspase-3 activity in Jurkat cells ( Figure 5b ). TRAIL (50 nM) induced caspase-3 activity that reached a maximum at 6 h, and thereafter declined. When cells were pretreated with CsA (10 mM), TRAIL-induced caspase-3 activity was signi®cantly delayed, reached a maximum at about 12 h, and thereafter declined. We next examined the eects of CsA on TRAIL-induced apoptosis in Jurkat cells ( Figure 5c ). CsA (10 mM) delayed, but did not block, TRAIL-induced apoptosis. These data clearly demonstrate that TRAIL-induced apoptosis can occur without the involvement of mitochondria, but mitochondria is also involved in TRAIL-induced apoptosis.
XIAP, CrmA and p35 inhibit TRAIL-induced caspase-3 activation and apoptosis
The human XIAP, cIAP-1, and cIAP-2 proteins can bind to and directly inhibit selected caspases. The caspase identi®ed as targets of these IAP family proteins thus far include caspases-3, -7, and -9 but not caspases-1, -2, -8 or -10 ( Roy et al., 1997; Deveraux et al., 1998; Deveraux and Reed, 1999) . The IAPs are known to block cell death induced by various stimuli (LaCasse et al., 1998; Deveraux and Reed, 1999; . Human leukemic U937 cells were stably transfected with either Neo or XIAP cDNA to examine the eects of XIAP on TRAIL-induced caspase-3 (Figure 6a and b) . The baculovirus protein p35 inhibits drug-induced apoptosis in eukaryotic cells (Nicholson et al., 1995; Bertin et al., 1996) . Overexpression of cowpox virus CrmA also prevents FAS-or TNFa-induced apoptosis (Tewari et al., 1995a,b; Enari, 2000) . We therefore examined the eects of CrmA and p35 on TRAIL-induced apoptosis. Overexpression of CrmA or p35 inhibited TRAIL-induced apoptosis in a dose-dependent manner (Figure 6c ). These data suggest that regulation of TRAIL-induced apoptosis by XIAP is conserved and similar to that of the Fas/FasL system.
Effects of Bcl-2 or Bcl-X L on TRAIL-induced apoptosis and mitochondrial functions
Mitochondria appear to play an important role in the early events of apoptosis (Green and Reed, 1998; Kroemer et al., 1998) . Both mitochondrial depolarization and the loss of cytochrome c from the mitochondrial intermembrane space have been proposed as early Figure 3 Time course of recruitment of FADD and caspase-8 to TRAIL receptors. (a) MCF-7 cells were treated with 50 nM of recombinant Hist-tagged soluble TRAIL (sTRAIL) for the indicated time points and then lysed (see Materials and methods). The assembled death inducing signaling complex (DISCs) were immunoprecipitated with anti-5X His antibody and protein A Sepharose, and analysed by Western blot analysis using antibodies to DR4, DR5, FADD, caspases-8 and -10. In unstimulated controls (7), sTRAIL was added after lysis to immunoprecipitate non-stimulated TRAIL receptors. Two distinct DR5 species, which probably correspond to the two alternatively spliced forms, were detected (Screaton et al., 1997) . Cell extracts were analysed for the presence of FADD and caspase-8 before (7) central events in apoptotic cell death (Green and Reed, 1998; Kroemer et al., 1998) . The anti-apoptotic gene Bcl-2 or Bcl-X L protects cancer cells from apoptosis induced by a variety of anticancer agents (Decaudin et al., 1997; Kluck et al., 1997; Simonian et al., 1997; Adams and Cory, 1998; Srivastava et al., 1999a,b,c) . Since Bcl-2 and Bcl-X L have been shown to localize to the outer mitochondrial membrane (Korsmeyer, 1999; Srivastava et al., 1999c) , the eects of Bcl-2 or Bcl-X L overexpression on apoptosis, cytochrome c redistribution, and mitochondrial membrane depolarization in response to TRAIL were investigated (Figure 7) . We ®rst compared the apoptosis-inducing potential of TRAIL and etoposide in Jurkat cells stably transfected with either Bcl-2, Bcl-X L or vector alone as described 
of three independent experiments
Oncogene TRAIL-induced apoptosis A Suliman et al elsewhere (Srivastava et al., 1999c) . Overexpression of Bcl-2 or Bcl-X L in Jurkat cells inhibited TRAILinduced apoptosis in a dose-dependent manner at 24 h (Figure 7a) . Interestingly, when cells were treated with TRAIL for various time points (up to 60 h), Bcl-2 or Bcl-X L delayed, but did not inhibit, TRAIL-induced apoptosis in Jurkat cells (Figure 7b ). In contrast, overexpression of Bcl-2 or Bcl-X L in Jurkat cells almost completely abrogated apoptosis induced by etoposide (Figure 7c ). Since Bcl-2 or Bcl-X L delayed TRAIL-induced apoptosis in Jurkat cells, we examined whether these genes would inhibit TRAIL-induced apoptosis in MCF-7 cells. Again, overexpression of Bcl-2 or Bcl-X L delayed, but did not inhibit, TRAILinduced apoptosis in MCF-7 cells (Figure 7d ). These data provides further evidence that TRAIL can induce apoptosis (delayed apoptosis at 60 h) via a mitochondrial-independent pathway, whereas etoposide-induced apoptosis is inhibited by overexpression of Bcl-2 or Bcl-X L at the level of mitochondria. However, it should be noted that overexpression of genes may have delaying eects on cell death. Thus, although a conventional anti-tumor drug failed to kill Bcl-2-and Bcl-X L -overexpressing cancer cells eciently, these cells remain highly sensitive to TRAIL-induced apoptosis.
We next determined the presence of cytochrome c in the cytosolic and mitochondrial fractions of cells treated with TRAIL. The subcellular localization of cytochrome c, which normally resides in the mitochondrial intermembrane space, was ®rst assessed at various times following TRAIL treatment. Treatment of wild type Jurkat cells or JT/Neo with TRAIL resulted in the release of cytochrome c from the mitochondria to cytosol in a time-dependent manner (data not shown). In Jurkat cells, the release of cytochrome c began at 1 h and reached a plateau at 4 h (data not shown). Two hours after 50 nM TRAIL treatment, Jurkat cells did not undergo apoptosis as measured by DAPI staining (data not shown). We next examined the eects of Bcl-2 or Bcl-X L on cytochrome c release after 6 h of 50 nM TRAIL treatment (Figure 7e ). There was no cytochrome c in the cytosol of untreated JT/Neo, JT/Bcl-2 and JT/Bcl-X L cells (Figure 7e ). However, when cells were treated with TRAIL (50 nM) for 6 h, cytochrome c was detected in the cytosol of JT/Neo, JT/Bcl-2 and JT/Bcl-X L cells (Figure 7e) . Interestingly, the amount of cytochrome c in the mitochondrial fraction was same as in the cytosolic fraction in JT/ Neo, JT/Bcl-2 and JT/Bcl-X L cells.
Treatment of JT/Neo cells with TRAIL produced a steady decline in Dc m (Figure 7f) . Within 6 h, more than 40% of the dye was lost from the cells (Figure 7f ). The time-dependent loss of DiOC 6 (3)¯uorescence in Jurkat cells due to TRAIL treatment was delayed, but not prevented, by the overexpression of Bcl-2 or Bcl-X L (Figure 7f ). As expected, TRAIL had no eect on Dc m in Jurkat cells de®cient in FADD or caspase-8 (Figure 7g ). These data suggest that Bcl-2 and Bcl-X L may delay the release of mitochondrial factors required for caspase activation, except caspase-8.
Discussion
Apoptosis can be induced by both mitochondrialdependent and -independent pathways Krammer, 1999; Peter et al., 1999) . In addition, mitochondria contribute to and, at least in some cellular systems, seem to be necessary for execution of death receptor-induced apoptosis (Scadi et al., 1998) . However, the degree of mitochondrial contribution in TRAIL-induced apoptosis has not been investigated. Here, we provide biochemical and functional evidence that mitochondrial dysfunction occurs, but not essential, during TRAIL-induced apoptosis. Activation of caspase-8 by TRAIL can lead to two signals: (1) a mitochondrial-independent signal that activates caspases downstream of caspase-8; and (2) a mitochondrial-dependent caspase activation following caspase-8 activation and BID cleavage. Bcl-2 and Bcl-X L appear to maintain mitochondrial function resulting in drug-resistance in various cell lines (Decaudin et al., 1997; Simonian et al., 1997; Adams and Cory, 1998; Srivastava et al., 1999a,c) , these cells retain their sensitivity against TRAIL. In addition, we demonstrate that DR4-and DR-5-mediated apoptosis depends critically upon FADD and caspase-8. While this manuscript was in preparation, our ®ndings for the involvement of FADD and caspase-8 in TRAIL-DISC have been con®rmed by others (Bodmer et al., 2000; Kischkel et al., 2000; Sprick et al., 2000) .
Although our analysis of the DR-DISC provides support for the importance of caspase-8 in TRAILinduced apoptosis, it failed to identify a similar function for caspase-10, which was suggested by overexpression studies (Pan et al., 1997a; Wang et al., 1999) and by the ®nding that dendritic cells expressing a mutant caspase-10 are resistant to TRAIL signaling . The TRAIL signaling pathway may therefore dier in cells from dierent origins. Alternatively, a catalytically inactive caspase-10 mutant may act as a non-releasable substrate trap for caspase-8, thereby inactivating the caspase, as has been proposed for FLIP (Irmler et al., 1997) . Caspase-10 and FLIP share an overall structural homology. This would also explain the unexpected ®nding that mutant caspase-10 blocks Fas signaling . According to our studies on the assembly of TRAILreceptor DISC, it can be suggested that FADD and caspase-8 are important constituents of DISC.
Ligation of Fas can also play a role in chemotherapeutic drug-induced apoptosis in epithelial cells, since FAS and/or FasL are up-regulated following exposure of cells to etoposide (Kasibhatla et al., 1998) and microtubule-damaging drugs (Srivastava et al., 1999b) . Both FADD and caspase-8 are involved in FASinduced apoptosis (Schulze-Ostho et al., 1998). The expression of DR4 and/or DR5 is more highly regulated than Fas. Treatment of cells with chemotherapeutic drugs or ionizing radiation has been found to induce DR4 and/or DR5 (Chinnaiyan et al., 2000; Gibson et al., 2000; Kim et al., 2000) . Furthermore, combined treatment with etoposide and TRAIL gave a synergistic apoptotic response (Gibson et al., 2000) . Thus, activation of DR4 and DR5 plays a prominent role in anticancer drug-induced apoptosis in cancer cells.
Chemotherapeutic drugs are used in the treatment of most cancers; however, these drugs are only partially eective in the treatment of leukemia and solid tumors. Thus, new ways of treating cancer must be developed. Ligation of death receptors to induce apoptosis in tumor cells has been proposed as an eective way of treating epithelial cell derived cancers; unfortunately, the administration of death receptor ligands FasL and TNF has toxic eects (French and Tschopp, 1999; Walczak et al., 1999) . The discovery of DR4 and DR5, along with their ligand TRAIL, provided new death receptor family members that may oer less-toxic eects on noncancerous cells.
The caspases are critical protease mediators of apoptosis and thus represent important targets for anti-apoptotic intervention (Nicholson et al., 1995; Salvesen, 1999) . These highly conserved, aspartatespeci®c proteases are expressed as single-chain zymogens, which upon apoptotic signaling are activated by proteolytic processing, either by autoactivation, transactivation, or cleavage by other caspases (Green, 1998; Wolf et al., 1999) . Once activated, the caspases proteolytically cleave a multitude of cellular substrates, leading to apoptotic death. Thus, caspase activation is a key regulatory point in the commitment to apoptosis. The molecular mechanisms regulating caspase activation are largely unknown. Our data suggest that caspase-8 activation is essential for TRAIL-induced apoptosis. In addition, caspase-3 can be activated either by caspase-8 or mitochondrial events (e.g. release of cytochrome c) leading to apoptosis. TRAIL-induced caspase-3 activity may be partially dependent on caspase-8 activation. However, TRAIL-induced caspase-3 activation is sucient to cause apoptosis without the involvement of mitochondria, as cyclosporin A (CsA) delays, but does not block, caspase-3 activation and apoptosis. In other systems where apoptosis occurs via mitochondrial-dependent pathway, CsA blocks caspase-3 activation and apoptosis (Susin et al., 1998; He et al., 2000) . It is not known whether TRAIL induces early response gene. Recently, it has been shown that an early response gene TR3 (nuclear orphan receptor) tralslocates from nucleus to mitochondria to induce cytochrome c release and apoptosis (Li et al., 2000) . Mitochondrial targeting of TR3 seems to be essential for its proapoptotic eect (Li et al., 2000) . It is likely that the eects of TRAIL on mitochondria may require signals from nucleus to alter mitochondrial functions.
IAP family proteins have been identi®ed in baculoviruses, Drosophila, and humans where they function as suppressors of apoptosis (Hay et al., 1994; Clem and Miller, 1994; Rothe et al., 1995; Duckett et al., 1996; Uren et al., 1996; Liston et al., 1996; Roy et al., 1997) . The baculovirus protein p35 inhibits drug-induced apoptosis in eukaryotic cells (Nicholson et al., 1995; Bertin et al., 1996) . Overexpression of cowpox virus CrmA also prevented apoptosis due to engagement of the FAS (CD95) receptor or to exposure to TNFa (Tewari et al., 1995a,b; Enari, 2000) . Human XIAP, cIAP-1 and cIAP-2 proteins can bind to and directly inhibit selected caspases. The caspases identi®ed as targets of these IAP family proteins thus far include caspases-3, -7, and -9 but not caspases-1, -2, -8, or -10 ( Deveraux et al., 1997; Roy et al., 1997) . TRAIL activates primarily caspases-8, and -3 (and possibly caspase-9) , and it appears that XIAP can inhibit TRAIL-induced caspase-3 activity and apoptosis. In addition, CrmA and p35 can also inhibit TRAIL-
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A Suliman et al induced apoptosis. These diverse apoptotic inhibitors from mammals, insects, and their associated viral pathogens are providing important insight into the regulatory mechanisms of TRAIL-induced caspase activation and apoptosis. The Bcl-2 gene has been found to be overexpressed in the presence [t(14 : 18) chromosomal translocation] or absence of gene rearrangement in leukemia and lymphoma cells. Because most clinically administered chemotherapeutic drugs mediates apoptosis mainly by inducing mitochondrial dysfunction, tumor cell resistance is likely to include overexpression of Bcl-2 or Bcl-X L . These genes have been found to protect mitochondria and subsequent cross-resistance to many mitochondrial-targeting chemotherapeutic drugs. Bcl-2 or Bcl-X L can delay, but not inhibit, TRAIL-induced apoptosis (Keogh et al., 2000; Kim et al., 2001) , suggesting tumor cells that have already acquired resistance to chemotherapeutic drugs by Bcl-2 or Bcl-X L can be killed by TRAIL. Thus, TRAIL may be a promising candidate for the treatment of patients carrying drug-resistant tumors.
Materials and methods
Reagents
Recombinant soluble human TNF-related apoptosis-inducing ligand (TRAIL or Apo2L) was purchased from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA, USA). Antibodies against FADD, caspases-3, -8 and -10 were from Transduction Laboratory (Lexington, KY, USA). Antibodies against DR-4, DR-5 and BID were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 3,3' dihexyloxacarbocyanine iodide [DiOC 6 (3)] was from Molecular Probes, Inc. (Eugene, OR, USA). Anti-cytochrome c antibody and anti-PARP antibody were from Pharmingen (San Diego, CA, USA). Enhanced chemiluminescence Western blot detection reagents were from Amersham Life Sciences Inc. (Arlington Heights, IL, USA). The caspase inhibitors z-IETD-fmk (z-IleGlu-Thr-Asp-¯uoromethylketone), z-DEVD-fmk (CBZ-AspGlu-Val-Asp-¯uoromethylketone) and z-VAD-fmk (CBZVal-Ala-Asp-¯uoromethylketone), and inactive peptide z-FA-fmk (CBZ-Phe-Ala-¯uoromethylketone) were from Enzyme Systems Products (Livermore, CA, USA). Cyclosporin A (CsA) and z-LEHD-fmk (z-Leu-Glu(Ome)-His-Asp(Ome)-uoromethylketone) were purchased from Calbiochem (La Jolla, CA, USA). All other chemicals used were of analytical grade and were purchased from Fisher Scienti®c (Suwanee, GA, USA) or Sigma (St. Louis, MO, USA). The nucleosome ELISA assay kit was from Oncogene Research Products (Cambridge, MA, USA). The caspase-3 assay kit was purchased from Clontech Laboratories, Inc. (Palo Alto, CA, USA).
Cells and culture conditions
Jurkat T cells, U937, and MCF-7 cells were obtained from American Type Culture Collection (Rockville, MD, USA). Cells were cultured in RPMI 1640 tissue culture medium (BioWhittaker Inc., Walkersville, MD, USA) supplemented with 2 mM L-glutamine, 10% fetal bovine serum and 1% penicillin-streptomycin mixture at 378C with 5% CO 2 .
Transfection of Bcl-2 and Bcl-X L genes
Jurkat T lymphocytes were transfected with pSFFVneo-Bcl-2, pSFFVneo-Bcl-X L or pSFFV-neo plasmids as described elsewhere (Srivastava et al., 1999c) . The cDNAs for Bcl-2 and Bcl-X L were provided by Dr Craig Thompson (University of Pennsylvania, Philadelphia, PA, USA) and Dr Stanley Korsmeyer (Dana-Farber Cancer Institute, Boston, MA, USA), respectively. U937 cells were infected with CrmA or p35 as described elsewhere (Datta et al., 1997) . U937 cells were transfected with the full-length myc-tagged XIAP cDNA (provided by Dr John Reed, The Burnham Institute, La Jolla, CA, USA).
Measurement of mitochondrial energization
Mitochondrial energization was determined by retention of 3,3'-dihexyloxacarbocyanine [DiOC 6 (3)] (Srivastava et al., 1999c) . Cells (5610 5 in 500 ml of complete RPMI 1640 medium) were loaded with 40 nM DiOC 6 (3) during the last 30 min of treatment, the cells isolated at 7006g for 10 min, the cell pellet resuspended and washed in PBS two times. Cells were lysed by addition of 600 ml of deionized water followed by mechanical homogenization. The concentration of retained DiOC 6 (3) was determined on a¯uorescence spectrometer at 480 nm excitation and 510 nm emission (Srivastava et al., 1999c) .
Subcellular fractionation
Mitochondria and cytosolic (S100) fractions were prepared by resuspending cells in 0.8 ml ice-cold buer A (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 17 mg/ml phenylmethylsulfonyl¯uoride, 8 mg/ml aprotinin, 2 mg/ml leupeptin, pH 7.4] (Srivastava et al., 1999c) . Cells were passed through an ice-cold cylinder cell homogenizer. Unlysed cells and nuclei were removed by centrifugation at 7506g for 10 min. The supernatant was spun at 10 0006g for 25 min, and the mitochondrial pellet resuspended in buer A. The supernatant was spun at 100 0006g for 1 h. The supernatant from this ®nal centrifugation represented the S100 fraction.
DISC analysis
The cells were collected, washed with ice-cold PBS and lysed in lysis buer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.2% Nonidet P40, 10% glycerol and complete protease inhibitor cocktail) for 15 min on ice. The lysate was cleared twice by centrifugation at 16 0006g for 10 min at 48C. The soluble fraction was precleared with 20 ml Sepharose for 2 h at 48C and immunoprecipitated with 20 ml anti-5X His antibody and protein-A-Sepharose for 4 h to overnight at 48C. Beads were recovered by centrifugation, washed four times with 500 ml lysis buer without protease inhibitors, resuspended in 600 ml 0.1 M citrate-NaOH, pH 2.7, containing 50 mg/ml lysozyme as a carrier, incubated for 5 min at room temperature and sepharose beads removed by centrifugation. The supernatant was precipitated with 750 ml chloroform:methanol (1 : 4) and centrifuged at 12 0006g for 5 min. The upper phase was discarded, replaced with an equal volume of methanol and proteins recovered by centrifugation at 16 0006g for 3 min. The pellet was redissolved by sonication in sample buer, and analysed by SDS ± PAGE and Western blotting. For analysis of DR4 and DR5 expression, cells were subjected to phase separation in Triton X-114 (Bordier, 1981) , and analysed as described above.
Western blot analysis
Cells were lysed in a buer containing 10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.5 mM EDTA, 1 mM EGTA, 1% SDS, 1 mM sodium orthovanadate, and a mixture of protease inhibitors (1 mM phenylmethylsulfonyl¯uoride, 1 mg/ml pepstatin A, 2 mg/ml aprotinin). Lysates were sonicated for 10 s, centrifuged for 20 min at 12 0006g and stored at 7708C. Equal amounts of lysate protein were run on 10% SDS ± PAGE gels and electrophoretically transferred to nitrocellulose. Nitrocellulose blots were blocked with 10% nonfat dry milk in TBST buer (20 mM Tris-HCl (pH 7.4), 500 mM NaCl, and 0.01% Tween 20) and incubated with primary antibody in TBST containing 5% bovine serum albumin overnight at 48C. Immunoreactivity was detected by sequential incubation with horseradish peroxidase-conjugated secondary antibody and ECL reagents.
Nucleosome ELISA assay
The nucleosome ELISA allows quantitation of apoptotic cells in vitro by DNA anity-mediated capture of free nucleosomes followed by their anti-histone-facilitated detection. In this assay, mono-and oligo-nucleosomes are captured on precoated DNA-binding proteins. Cells (2610 6 ) were seeded into 24-well plates in the presence or absence of various drugs for 36 h (see ®gure legends). Cells were harvested for nucleosome ELISA assay according to the manufacturer's directions (Oncogene Research Products, Cambridge, MA, USA). Brie¯y, anti-histone 3 biotin-labeled antibody binds to the histone component of captured nucleosomes and is detected following incubation with streptavidin-linked horseradish peroxidase conjugate. HRP catalyzes the conversion of colorless tetramethylbenzidine to blue and addition of a stop solution changes the color to yellow, the intensity of which is proportional to the number of nucleosomes in the sample.
